| Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis |
Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! |
fool.com |
2025-05-14 23:30:00 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone |
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (“Blackstone”). Concurrent with this new facility, Axsome has retired its previous term loan with Hercules Capital. |
globenewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years |
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance by buying shares of companies likely to beat broader equities. |
fool.com |
2025-05-12 11:08:00 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks in the Making |
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years. |
fool.com |
2025-05-11 15:15:00 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns |
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competitive depression market, but its success is heavily reliant on aggressive marketing and significant spending. Upcoming launches and regulatory submissions for Symbravo, AXS-14, AXS-05, and AXS-12 face stiff competition and potential regulatory hurdles. |
seekingalpha.com |
2025-05-06 16:48:47 |
Czytaj oryginał (ang.) |
| AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y |
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales. |
zacks.com |
2025-05-06 14:41:06 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript |
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Graig Suvannavejh - Mizuho Securities Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Troy Langford - TD Cowen Ami Fadia - Needham & Company Operator Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast. |
seekingalpha.com |
2025-05-05 15:44:27 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 |
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million. |
benzinga.com |
2025-05-05 14:41:49 |
Czytaj oryginał (ang.) |
| Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates |
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-05 14:35:51 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates |
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago. |
zacks.com |
2025-05-05 13:15:38 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO ® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol in ADHD announced Initiation of Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness anticipated in 2025 Positive topline results of EMERGE Phase 3 trial of SYMBRAVO in migraine patients with prior inadequate response to oral CGRP inhibitors announced Company to host conference call today at 8:00 AM Eastern NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first quarter of 2025 and provided a general business update. “The first quarter was strong and eventful, with the approval of SYMBRAVO for the acute treatment of migraine, continued growth of AUVELITY and SUNOSI, and significant advancements across our broad late-stage neuroscience pipeline,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month |
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline |
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-28 15:06:01 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics to Participate in Upcoming Investor Conferences |
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May: |
globenewswire.com |
2025-04-22 11:00:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm |
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders. |
globenewswire.com |
2025-04-16 18:03:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm |
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. |
globenewswire.com |
2025-04-16 18:00:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm |
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. |
globenewswire.com |
2025-04-10 15:03:00 |
Czytaj oryginał (ang.) |
| Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? |
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-04-10 14:55:43 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm |
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times. |
prnewswire.com |
2025-04-08 18:03:00 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 |
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. |
globenewswire.com |
2025-04-08 11:00:00 |
Czytaj oryginał (ang.) |
| Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs |
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint. |
benzinga.com |
2025-02-24 15:34:22 |
Czytaj oryginał (ang.) |
| Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering |
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering |
seekingalpha.com |
2025-02-20 10:15:00 |
Czytaj oryginał (ang.) |
| Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth |
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year. |
zacks.com |
2025-02-18 14:30:34 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript |
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Ari Maizel - Chief Commercial Officer Mark Jacobson - Chief Operating Officer Hunter Murdock - General Counsel Conference Call Participants Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald Asim Rana - Truist Securities Joseph Thome - TD Cowen David Hoang - Deutsche Bank David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Graig Suvannavejh - Mizuho Securities Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Cerena Chen - Wells Fargo Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Operator Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. |
seekingalpha.com |
2025-02-18 13:12:42 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates |
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago. |
zacks.com |
2025-02-18 11:15:19 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Revenue Surges 66% |
Biopharmaceutical firm Axsome Therapeutics (AXSM -0.40%) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales hitting $118.8 million, surpassing analyst estimates of $118 million. |
fool.com |
2025-02-18 10:06:33 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? |
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week. |
zacks.com |
2025-02-17 12:30:34 |
Czytaj oryginał (ang.) |
| This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? |
It's only mid-February, but as of this writing biotech company Axsome Therapeutics (AXSM -0.40%) is up by 55% year to date. Substantial stock-market gains over short periods aren't that rare in the industry. |
fool.com |
2025-02-16 11:45:00 |
Czytaj oryginał (ang.) |
| Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade |
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth. |
seekingalpha.com |
2025-02-11 19:20:43 |
Czytaj oryginał (ang.) |
| Why Axsome Therapeutics Stock Is Soaring Today |
Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. |
fool.com |
2025-02-11 13:39:06 |
Czytaj oryginał (ang.) |
| Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline |
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-11 13:06:34 |
Czytaj oryginał (ang.) |
| Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva |
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. |
zacks.com |
2025-02-11 10:41:07 |
Czytaj oryginał (ang.) |
| Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains? |
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-02-11 06:36:08 |
Czytaj oryginał (ang.) |
| Why Axsome Therapeutics Stock Is Skyrocketing Today |
Shares of Axsome Therapeutics (AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. |
fool.com |
2025-02-10 16:45:31 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' |
On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA. |
benzinga.com |
2025-02-10 14:33:47 |
Czytaj oryginał (ang.) |
| Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises |
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio. |
zacks.com |
2025-01-31 13:56:11 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader |
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack. |
globenewswire.com |
2025-01-31 09:00:00 |
Czytaj oryginał (ang.) |
| US FDA approves Axsome Therapeutics' migraine drug |
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. |
reuters.com |
2025-01-30 17:55:39 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults |
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours |
globenewswire.com |
2025-01-30 17:45:00 |
Czytaj oryginał (ang.) |
| Axsome Shares Rise 19% in a Month: What's Driving the Rally? |
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business. |
zacks.com |
2025-01-24 13:36:12 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results |
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, supporting a bullish outlook. |
seekingalpha.com |
2024-12-31 11:15:44 |
Czytaj oryginał (ang.) |
| Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results |
On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. |
benzinga.com |
2024-12-31 10:15:46 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session |
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday. |
benzinga.com |
2024-12-30 10:13:20 |
Czytaj oryginał (ang.) |
| Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study |
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial. |
reuters.com |
2024-12-30 09:15:55 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation |
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) |
globenewswire.com |
2024-12-30 09:00:00 |
Czytaj oryginał (ang.) |
| Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? |
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:35 |
Czytaj oryginał (ang.) |
| Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data |
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters. |
seekingalpha.com |
2024-11-29 12:32:32 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says |
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial. |
benzinga.com |
2024-11-27 15:23:19 |
Czytaj oryginał (ang.) |
| Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up |
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity. |
zacks.com |
2024-11-13 14:10:17 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript |
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Cerena Chen - Wells Fargo David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Myles Minter - William Blair Poorna Kannan - Needham & Company Joel Beatty - Baird Graig Suvannavejh - Mizuho Securities Matt Kaplan - Ladenburg Thalmann Operator Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-12 16:02:40 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell |
Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axsome's profitability remains distant, with significant cash burn and competition from pharma giants. AXS-07 is likely to gain FDA approval in January for migraine treatment, while AXS-05 shows potential for Alzheimer's agitation, but “blockbuster” revenue status is uncertain. |
seekingalpha.com |
2024-11-12 15:17:13 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates |
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago. |
zacks.com |
2024-11-12 11:16:12 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts? |
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week. |
zacks.com |
2024-11-11 13:50:15 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 |
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado. |
globenewswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for |
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-05 13:05:49 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 |
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts. |
globenewswire.com |
2024-10-29 09:00:00 |
Czytaj oryginał (ang.) |
| 3 Bargain Stocks to Buy in a Market That's Priced for Perfection |
Yes, bargains can still be found in the stock market. |
fool.com |
2024-10-19 11:30:00 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 |
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. |
globenewswire.com |
2024-10-15 11:00:00 |
Czytaj oryginał (ang.) |
| Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition? |
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern. |
zacks.com |
2024-10-11 14:40:41 |
Czytaj oryginał (ang.) |
| 1 Under-the-Radar Biotech Stock to Buy and Hold |
Axsome Therapeutics' revenue is growing rapidly. The company's pipeline should lead to many new approvals and label expansions. |
fool.com |
2024-09-29 11:32:00 |
Czytaj oryginał (ang.) |